Latest MediciNova News & Updates

See the latest news and media coverage for MediciNova. We track all announcements, press releases, and industry mentions in real time, all in one place.

MediciNova

Biopharmaceutical company focused on neurology, respiratory, and liver diseases

medicinova.com

Headquarters: La Jolla, United States
Company type: Public company
Number of employees: 15–50

Last updated Today

Latest news about MediciNova

In short: MediciNova advanced its clinical pipeline, securing a glioblastoma patent and completing enrollment for major ALS and hypertriglyceridemia trials.

Company announcements

June 8 MediciNova

MediciNova receives patent allowance for MN-166 combination therapy

The patent covers use with anti-PD-1 antibodies for glioblastoma treatment, expiring in 2042.

May 13 MediciNova

MediciNova is advancing MN‑166 for ALS treatment

The drug targets neuroinflammatory pathways to slow disease progression and preserve motor function.

May 6 MediciNova

MediciNova announces ibudilast study in Cancer Research

The peer-reviewed study highlights ibudilast inhibiting MIF-mediated reprogramming in brain metastasis models, identifying MIF as a biomarker.

April 30 MediciNova

MediciNova collaborates with Mayo Clinic on ALS program

The SEANOBI EAP evaluates MN-166 (ibudilast) for ALS patients, generating real-world data complementing the COMBAT-ALS study.

Media coverage

May 26 Stockhouse

MediciNova Given Notice of Monetary Damages Due Under Patent Settlement of Sanofi-Novartis

LA JOLLA, Calif., Nov. 11, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard...

May 15 Yahoo Finance

MN-166 Sales Forecast and Market Size Analysis Report 2026-2034 with Focus on United States, Germany, France, Italy, Spain, United Kingdom, and Japan

MN-166 presents market opportunities through its multi-indication strategy, including ALS, MS, and more, supported by pivotal trials, regulatory incentives like Orphan Drug and Fast Track...

May 14 Yahoo Finance

MediciNova: Q1 Earnings Snapshot

MediciNova Inc. MNOV) on Thursday reported a loss of $2.6 million in its first quarter.

April 2 NeurologyLive

Ibudilast Slows Retinal Thinning in Progressive MS | NeurologyLive - Clinical Neurology News and Neurology Expert Insights

New analyses from the phase 2b SPRINT-MS trial suggest that MediciNovas ibudilast (also known as MN-166), can lessen retinal thinning as measured by optical coherence...

Never miss news about MediciNova

Track MediciNova and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Trending companies

Discover what's making headlines across other trending companies.